[Objective] To identify a mimicking alloantibody, analyze its serological characteristics and antibody specificity, and explore transfusion strategies for mimicking alloantibody. [Methods] The antibody specificity of patients was identified by direct anti-globulin test, antibody identification, antibody titration test and absorption-elution test. Related literature was retrospectively reviewd. [Results] The anti-Ec was detected in both the diluted serum and elution liquid. The patient's antibody corresponded to antigen negative red blood cells (type O, CCDee) from blood donors who absorb serum and elute anti-Ec. In both serum and elution liquid, the titer detected by E-positive cells was stronger than that by E-negative cells, with a difference of 5-6 tubes in the serum and a difference of 2 tubes in the elution liquid. Thirty articles at home and abroad were reviewed and analyzed, revealing that the distribution of mimicking specificity autoantibodies was mainly in the Rh blood group system, accounting for 86.4%, followed by blood type systems such as Kidd, MNS, Duffy, etc. [Conclusion] The presence of mimicking anti-Ec antibody in the patient's serum was confirmed, with specific and non-specific anti-E antibodies in the mimicking antibody. Reasonable use of antibody titer test, and absorption-elution test can help identify the specificity of anti-E antibodies and provide transfusion strategies for clinical transfusion.

Objective: To evaluate the reduction of the residual risk of blood transfusion- transmitted hepatitis B virus (HBV), using nucleic acid detection(NAT)test for enzyme linked immunosorbent assay (ELISA) qualified volunteer-donor bloods in Quzhou area after NAT was developed. Methods: Specimens were collected from March 2016 to March 2017, detected by ELISA twice with two different reagents and NAT only once. The residual risks of blood transfusion-transmitted HBV infection were calculated by mathematical model of risk evaluation. Results: Totally 27 646 specimens were collected from March 2016 to March 2017, which included 76 specimens that were both ELISA and NAT positive, 31 specimens were ELISA negative but NAT positive.The total number of NAT positive specimens was 107.The residual risk of HBV by ELISA test was 28.2×10 ^-5and NAT test was 13.0×10^-5. Conclusions NAT detection can greatly reduce the residual risk of blood transfusion-transmitted HBV infection, and provide effective value for bloods safety in practice.